Evidence map›Paper›PMID 39219694›Full record

ArticleDrug design, development and therapy2024

Enhance the Antimycobacterial Activity of Streptomycin with Ebselen as an Antibiotic Adjuvant Through Disrupting Redox Homeostasis.

Chuanjiang Dong, Yueqing Wang, Yi Cai, Yuhuang Wu, Wei Chen, Lu Wang, Xiaowen Liu, Lili Zou, Jun Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Secreted proteins ofFrontiers in tuberculosis · 2026
    Review
  2. Article
  3. Pathogenesis of Cutaneous Mycobacterial Infections-International journal of molecular sciences · 2025
    Review
  4. Journal of bacteriology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chuanjiang Dong *Department of Urology, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, Guangdong province, 523718, People's Republic of China.
Yueqing Wang *Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, Hubei Province, 443002, People's Republic of China.ORCID 0000-0002-9507-6563
Yi Cai *Department of Laboratory Medicine, Xiaogan Central Hospital, Xiaogan, Hubei Province, 432099, People's Republic of China.
Yuhuang WuHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, Hubei Province, 443002, People's Republic of China.
Wei ChenHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, Hubei Province, 443002, People's Republic of China.
Lu WangHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, Hubei Province, 443002, People's Republic of China.
Xiaowen LiuHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, Hubei Province, 443002, People's Republic of China.
Lili ZouHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Science, China Three Gorges University, Yichang, Hubei Province, 443002, People's Republic of China.ORCID 0000-0003-1393-0971
Jun WangThe Second People's Hospital of China Three Gorges University, Yichang, Hubei Province, 443002, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Tuberculosis (TB) remains a major health threat worldwide, and the spread of drug-resistant (DR) TB impedes the reduction of the global disease burden. Ebselen (EbSe) targets bacterial thioredoxin reductase (bTrxR) and causes an imbalance in the redox status of bacteria. Previous work has shown that the synergistic action of bTrxR and sensitization to common antibiotics by EbSe is a promising strategy for the treatment of DR pathogens. Thus, we aimed to evaluate whether EbSe could enhance anti-TB drugs against Methods: Minimum inhibitory concentrations (MIC) of isoniazid (INH), rifampicin (RFP), and streptomycin (SM) against Results: The results reveal that EbSe acts as an antibiotic adjuvant over SM on Conclusion: The above studies suggest that EbSe significantly enhanced the anti-

Indexed as

HomeostasisIsoindolesMicrobial Sensitivity TestsOrganoselenium CompoundsOxidation-ReductionStreptomycinAnimalsAnti-Bacterial AgentsAntitubercular AgentsAzolesDose-Response Relationship, DrugMiceMice, Inbred BALB CMolecular StructureMycobacterium marinumStructure-Activity RelationshipAnti-Bacterial AgentsAntitubercular AgentsAzolesebselenIsoindolesOrganoselenium CompoundsStreptomycinantibiotic adjuvantEbselenreactive oxygen speciesthioredoxin reductase

Identifiers

PMID39219694
PMCPMC11365518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.